This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 77 entries.
Botanix (ASX $BOT) Executive Director, Matt Callahan, spoke with BBC journalist, Vivienne Parry, at the 2022 Edison Open House: Global Healthcare virtual event this week. He detailed how the Company is harnessing valuable commercial opportunities in its dermatology and antimicrobial programs: “This is a great time to be in dermatology. There’s a real dearth of […]
Botanix is one of only 34 companies selected to participate in the 2022 Edison Open House: Global Healthcare virtual event to be hosted by the Edison Group next week. Join Botanix’s Executive Director, Matt Callahan, and science journalist, Vivienne Parry, at 7pm AEST on Tuesday 25th January 2022, as they discuss the upcoming developments for […]
At Botanix, we genuinely believe in the therapeutic potential of CBD to treat serious medical conditions … and clearly we’re not alone. Last month, pharmaceutical company Pfizer announced its entry into the cannabinoid space after sharing news of its planned acquisition of clinical-stage company Arena Pharmaceuticals for a total equity value of around US$6.7 billion. […]
While the world continues to battle COVID-19, experts are concerned that older, sick and vulnerable patients may be at increased risk of AMR. According to an article in The Lancet, 1 in 7 patients hospitalised with COVID-19 have “acquired a dangerous secondary bacterial infection, and 50% of patients who have died had such infections.” At […]
Botanix has today released an updated corporate presentation to the ASX, to support a non-deal investor roadshow underway this week. The latest developments in our antimicrobial resistance (AMR) and dermatology R&D programs, include: Progress with our BTX1801 antimicrobial program and plans for Phase 2 clinical studies in early 2022 Advancement of our BTX1702 clinical trial […]
According to WHO Director-General Tedros Adhanom Ghebreyesus, antimicrobial resistance is “one of the greatest health threats humanity faces today”. The Center for Disease Control and Prevention (CDC) estimates that each year in the U.S., at least 2.8 million people get an antibiotic-resistant infection, and more than 35,000 people die. The reality is, #AMR can affect […]
With a successful track record of commercialising therapies in the antimicrobial space, and over 18 years of experience in senior commercial leadership within the pharmaceutical sector, Lynda Berne is well equipped to lead the commercial strategy for Botanix’s antimicrobial asset BTX1801. “BTX1801 is an extremely interesting therapy, as it is the first and only CBD […]
Botanix Pharmaceuticals (ASX:BOT) is today hosting its Annual General Meeting (AGM) at 9:00am AWST at the offices of BDO, 38 Station Street, Subiaco, WA. To coincide with this event, the Company has shared an updated corporate presentation, which consolidates its progress in the past financial year and the valuable opportunities Botanix is pursuing in dermatology […]
Botanix President and Executive Chairman, Vince Ippolito, was interviewed by Christine Corrado from Proactive’s New York studio yesterday. Their conversation focused on the recent launch of our BTX 1204A canine study for atopic dermatitis and our BTX 1702 rosacea study in Australia and New Zealand. In commenting on the potential for the atopic dermatitis study, […]
Botanix Pharmaceuticals (ASX:BOT) has today provided an update on its dermatology program, focusing on the BTX 1204A canine study for atopic dermatitis and BTX 1702 rosacea study. The BTX 1204A canine study for atopic dermatitis has now been launched. This will enrol 45 canines and evaluate two formulations of BTX 1204A. Positive data from a […]
AUSTRALIA
Level 1, 50 Angove Street, North Perth WA 6006
USA
3602 Horizon Drive, Suite 160, King of Prussia, PA 19406
Be notified of important news from Botanix.
AU +61 8 6555 2945
US + 1 445 300 3403
info@botanixpharma.com